TITLE

Prevalence of Metabolic Syndrome in Patients with HIV in the Era of Highly Active Antiretroviral Therapy

AUTHOR(S)
LOMBO, BERNARDO; ALKHALIL, IMRAN; GOLDEN, MARJORIE P.; FOTJADHI, IRMA; RAVI, SREEDHAR; VIRATA, MICHAEL; LIEVANO, MARTA; DIEZ, JOSE; GHANTOUS, ANDRE; DONOHUE, THOMAS
PUB. DATE
May 2015
SOURCE
Connecticut Medicine;May2015, Vol. 79 Issue 5, p277
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objectives: Since the introduction of combination antiretroviral therapy (cART) as the standard of care for HIV disease, there has been a precipitous decline in the death rate due to HIV/AIDS. The purpose of this study was to report the prevalence of metabolic syndrome in HIV infected patients. Methods: Retrospective, cross-sectional, observational study of 259 patients with HIV infection treated with cART from an urban community hospital. Metabolic syndrome prevalence was defined using the International Diabetes Federation (IDF) and the U.S. National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria. Study patients were included regardless of the duration of cART. Results: The prevalence of metabolic syndrome was 27% using IDF criteria and 26% using ATP III criteria. Logistic regression analysis found an association between treatment with the protease inhibitor darunavir and metabolic syndrome. (OR 3.32 with 95% confidence interval between 1.54 and 7.15). Conclusion: There is a high prevalence of metabolic syndrome and obesity in HIV patients treated with cART, especially those taking the protease inhibitor darunavir.
ACCESSION #
102850103

 

Related Articles

  • superinfection a changing picture. Duffin, Ross // HIV Australia;Jun-Aug2004, Vol. 3 Issue 4, p9 

    Discusses the impact of superinfection on an individual's HIV disease progression. Overview of several HIV superinfection cases in Australia; Frequency of the occurrence of superinfection; Recommended approach to prevent HIV superinfection.

  • Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon. Ngatchou, William; Lemogoum, Daniel; Ndobo, Pierre; Yagnigni, Euloge; Tiogou, Emiline; Nga, Elisabeth; Kouanfack, Charles; de Borne, Philippe van; Hermans, Michel P. // Vascular Health & Risk Management;2013, Vol. 9, p509 

    Background: Human immunodeficiency virus (HIV) and its therapy are associated with increased aortic stiffness and metabolic syndrome (MetS) phenotype in Caucasian patients. We hypothesized that, independently of antiretroviral therapy, HIV infection in native black African patients is associated...

  • Health Economics in HIV Disease: A Review of the European Literature. Youle, M.; Trueman, P.; Simpson, K. // PharmacoEconomics;1999 Supplement 1, Vol. 15 Issue 5, p1 

    The costs of providing healthcare resources for patients with HIV disease have continued to rise during the last 2 decades since the first outbreak of AIDS. Although new and effective therapies have become available during this time, and are increasingly being used, outcome measures for, and the...

  • Accrued HIV evidence turns treatment dogma on its head. Check, Erika // Nature;8/21/2003, Vol. 424 Issue 6951, p866 

    Focuses on the possible health risk posed by HIV drugs in patients. Inefficacy of drugs in subduing virus in HIV positive patients; Comments of various researchers on HIV therapy; Thoughts over the distribution of drugs among various developing countries.

  • A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. Hahn, K.; Arendt, G.; Braun, J. S.; von Giesen, H.-J.; Husstedt, I. W.; Maschke, M.; Straube, E.; Schielke, E. // Journal of Neurology;Oct2004, Vol. 251 Issue 10, p1260 

    Background Painful HIV-associated sensory neuropathies (HIV-SN) are a common complication of HIV infection. The pathogenesis is unknown and the treatment very limited. Gabapentin (GBP) is effective in painful diabetic neuropathy and postherpetic neuralgia and its effectiveness on painful HIV-SN...

  • The Importance of Potency and Durability in HIV Patient Antiretroviral Therapy Preferences: A Telephone Survey. Sherer Jr., Renslow D.; Fath, Michael J.; Da Silva, Barbara A.; Nicolau, Ana-Maria; Miller, Nancy L. // AIDS Patient Care & STDs;Dec2005, Vol. 19 Issue 12, p794 

    Patients who were receiving or had received antiretroviral therapy (ART) participated in 45-minute telephone interviews to evaluate the importance of major treatment attributes. A Likert scale was used to quantify and rate the importance of 9 ART attributes. Trade-off exercises allowed...

  • One thousand words.  // CMAJ: Canadian Medical Association Journal;3/18/2003, Vol. 168 Issue 6, p748 

    Reports that only five percent of people with HIV/AIDS have access to life-prolonging medication. Efforts of the organization Doctors without Borders to gather financial support for struggling economies; Consideration of commercial rights such as patent protection.

  • Effect of Maintaining Highly Active Antiretroviral Therapy on AIDS Events among Patients with Late-Stage HIV Infection and Inadequate Response to Therapy. Gandhi, Tejal; Wei Wei; Amin, Kamal; Kazanjian, Powel // Clinical Infectious Diseases;3/15/2006, Vol. 42 Issue 6, p878 

    Background. We evaluated the effect of maintaining highly active antiretroviral therapy (HAART) on the development of new acquired immunodeficiency syndrome (AIDS)-related events in patients with late-stage human immunodeficiency virus (HIV) infection who had suboptimal CD4+ cell count and viral...

  • HIV Treatment Adherence and Sexual Functioning. Miguez-Burbano, Maria Jose; Espinoza, Luis; Lewis, John E. // AIDS & Behavior;Jan2008, Vol. 12 Issue 1, p78 

    To our knowledge, no studies have considered the bidirectional relationship between HIV infected patients’ social/sexual lives and HAART adherence. To determine it’s potential impact the study sample consisted of 135 men starting HAART and being followed for 6 months. Twenty...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics